Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Gemcitabine 15Mitomycin 10Docetaxel 7BCG Vaccine 7Cystoscopy 4tislelizumab 3durvalumab 3Radiotherapy 3Epirubicin 3disitamab vedotin 2avelumab 2Hyaluronic Acid 2tremelimumab 1toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1lornoxicam 1erdafitinib 1enzalutamide 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1VPM1002 recombinant BCG vaccine 1Urine Specimen Collection 1Ty21a typhoid vaccine 1Transurethral Resection of Bladder 1Therapeutics 1Surveys and Questionnaires 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Muscle Invasive Bladder Neoplasms × BCG Connaught × Clear all
NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

A.O.U. Città della Salute e della Scienza

Phase 2 Completed
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡